XYLEM
30.8.2022 20:01:39 CEST | Business Wire | Press release
Annabelle M. Rayson from Canada receives the prestigious 2022 Stockholm Junior Water Prize for her research on how to treat and prevent harmful algae blooms. HRH Crown Princess Victoria of Sweden announced the winner during a ceremony at World Water Week in Stockholm.
Harmful algae blooms plague aquatic ecosystems around the world. They impact water quality and ecosystem diversity, cause dead zones, and cost the fishing and tourism industries millions of dollars.
Rayson’s father, a commercial fisherman, could no longer fish in certain areas due to harmful algae blooms, so she undertook research to find a method to treat and prevent them.
Rayson learned the concept of biomanipulation, and which species of zooplankton was best to treat and prevent algae blooms. For this, she was announced as winner of Stockholm Junior Water Prize, an international competition where students between the ages of 15 and 20 present solutions to major water challenges.
Speaking on winning the prize, Rayson said: “It’s an absolute honour to be here with so many other brilliant young people, representing all the small-town little girls out there, dreaming of her own microscope and lab coat. Hey girls, we can still make it.”
The Jury noted that “the winning entry has a potential solution for a multi-faceted global problem. It is not just an issue for human health, but it also affects water courses and the species that live within them. Of the challenges we face in terms of public health, many are intimately intertwined with water quality, and the winner – dedicated, passionate and creative – has conducted extensive, bio-inspired research to address this pervasive issue.”
The winner was presented with her prize during an award ceremony at World Water Week by HRH Crown Princess Victoria of Sweden, the Prize’s Official Patron.
The Diploma of Excellence was awarded to Laura Nedel Drebes and Camily Pereira dos Santos from Brazil, for addressing the issue of period poverty – the inaccessibility to sanitary pads – with their development of sustainable and affordable sanitary pads from industrial by-products.
The People’s Choice Award went to Mishal Faraz from United Arab Emirates, completing the all-female line-up of winners.
The Stockholm Junior Water Prize has been organized every year since 1997 by the Stockholm International Water Institute, SIWI, with Xylem as Founding Partner.
“All Stockholm Junior Water Prize participants show passion and ingenuity that is truly inspiring and an important contribution towards a better future and a more water-wise world. Stockholm Junior Water Prize is a wonderful opportunity to celebrate these contributions,” said Torgny Holmgren, Executive Director at Stockholm International Water Institute.
Patrick Decker, President and CEO of Xylem, added: “On behalf of more than 17,000 Xylem colleagues around the world, I applaud all Stockholm Junior Water Prize 2022 participants, bringing their passion and their innovation to solve the world’s major water challenges. These students inspire us by embodying what’s possible when innovators from around the world come together – with bold ideas and conviction – to solve water.”
For more information: www.siwi.org/prizes
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220830005886/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom